The structure would be public, not private. We would therefore not be dependent on one company that might decide overnight to close its doors and set up elsewhere. The structure would be public and not-for-profit. The objective would be to push technologies forward in terms of industrial capacity and clinical trials. All clinical development could be done within that structure. Of course, the same would go for the funding. That's kind of the way I see things.
On February 16th, 2021. See this statement in context.